Verdad Advisers’s Crescent Biopharma CBIO Stock Holding History

Verdad Advisers’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,748	Closed	-$234K	–	241
2026 Q1	$234K	Buy	+12,748	New	+$146K	0.26%	122

Other funds holding CBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Verdad Advisers's CBIO Position: Q2 2026 in Review

Verdad Advisers sold out of Crescent Biopharma (CBIO) in Q2 2026, closing a stake of 12,748 shares — an estimated $234K sold.

Verdad Advisers first reported a position in CBIO in Q1 2026 and held it in 1 quarter. The position peaked at $234K in Q1 2026. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

Verdad Advisers reported no remaining Crescent Biopharma position as of Q2 2026 after selling out during the quarter.
Verdad Advisers sold 12,748 Crescent Biopharma shares in Q2 2026, an estimated $234K.
Verdad Advisers first reported a position in Crescent Biopharma in Q1 2026 and held it in 1 quarter.
Verdad Advisers's Crescent Biopharma position peaked at $234K in Q1 2026.
82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.